In a statement, the US biotech company’s president of severe genetic diseases Andrew Obenshain said bluebird will instead focus on the US market, highlighting the ‘challenges of achieving appropriate value recognition and market access for Zynteglo [betibeglogene autotemcel] in Europe’.
Bluebird received conditional marketing authorisation for Zynteglo in Europe in June 2019 – since then, it has failed to secure access agreements for the beta thalassaemia gene therapy in the market.
